Belimumab safety study for low CD4 counts and autoantibodies
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 1 study tests how safe belimumab is for people with idiopathic CD4 lymphopenia (low protective white blood cells) and signs of autoantibodies. It aims to learn whether the treatment is tolerable and could be a future option for people with this immune condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Be enrolled in the earlier study 09-I-0102
- Have idiopathic CD4 lymphopenia: very low CD4 counts (<300) on two tests 6 weeks apart, and still low within the last 90 days
- Have positive autoantibodies, such as a positive ANA test (or a study test for anti-immune-cell antibodies)
- If you could become pregnant and are female, use effective birth control starting at study start (or 30 days if on hormonal birth control) until 4 months after the last dose
- Be able to give informed consent and allow blood samples to be stored for future research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a long-acting IL-7 medicine to raise low CD4 immune cells in people with idiopathic CD4 lymphopenia. Because this is a dose-escalation study, the goal is to check safety and see if the treatment affects immune cell levels.
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
This study collects blood-forming cells from people with low CD4 counts and healthy volunteers to learn how the immune system works. It may help researchers better understand and treat conditions like idiopathic CD4 lymphocytopenia.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This study looks at people with systemic lupus (lupus) who have already started belimumab (a lupus medicine). It mainly focuses on whether participants who meet lupus diagnosis rules and choose to join can be followed in the study.
Hear when a new Idiopathic CD4 Lymphopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.